Watch this video to learn the process of generating and characterizing “humanized” NSG™ (Hu-NSG™) mice and view data demonstrating preclinical research applications of these novel mouse models.
Watch Video
Presented at the JAX Oncology Scientific Session, the author describes their study on humanized NSG™-(KbDb)null (IA)null mice, its characteristics, and use in immuno-oncology drug efficacy studies.
Watch Video
Presented at the JAX Oncology Scientific Sessions, the authors describe their work with humanized NSG™-Il-15 mice to evaluate natural killer (NK) cell-based drug efficacy studies.
Watch Video
Julia is a woman in her early 20s establishing care in your practice. During the course of your conversation, she tells you that she recently did an at-home ancestry test and was surprised when...
Learn More
Join Drs. Jing Jiao and Brian Soper for a discussion evaluating CAR T therapy efficacy in preclinical mouse models.
Watch Video
Frequently Asked Questions about CD34+ HSC Humanized Mice Humanized mouse models serve as an innovative and cost-effective platform to simulate trials, evaluate multiple drugs alone or in...
Learn More
Infection with HIV (human immunodeficiency virus) is the underlying cause of AIDS (acquired immunodeficiency syndrome). By 2014, nearly 37 million people worldwide were infected with HIV, and...
Learn More
Presented at the JAX Oncology Scientific Sessions, the authors describe their recent work using CD34+ NSG™ mice for bispecific antibody efficacy studies, and drug-induced cytokine release assays.
Watch Video
The challenge of a complex disease Acute myeloid leukemia (AML) is an aggressive cancer where functionally immature cells derived from the myeloid compartment undergo unchecked proliferation...
Learn More
Kyle Draheim, Ph.D. presents "Evaluating the Growth Kinetics, Histology, and Drug Response in PDX Breast Cancer Models Implanted Subcutaneously Versus in the Mammary Fat Pad"
Watch Video
Immuno-oncology – that is, pharmacologically stimulating a patient’s immune responses to destroy malignant tumor cells – has been a long hoped-for strategy for treating cancer. Compounds that...
Learn More
Jiwon Yang, Ph.D. presents "Effect of Aging on Toxicity, Efficacy, and Immunomodulation via Chemotherapy in C57BL/6J Syngeneic Model"
Watch Video
All that glitters… Cancer cells have found ingenious ways to evade the body’s immune system. These cells can shut off cytotoxic activity of anti-tumor T-cells, promoting their own...
Learn More
Jing Jiao, Ph.D. presents "Preclinical Mouse Model to Evaluate Efficacy and Potential Cytokine Release Syndrome of Chimeric Antigen Receptor (CAR) T Cell Therapy"
Watch Video
Watch Michael Brehm (University of Massachusetts Medical School) as he discusses highly immunodeficient NSG mouse models and their value in immuno-oncology and oncology research.
Watch Video
Presented at the JAX Oncology Scientific Sessions, Dr. Jing Jiao from JAX outlines her latest work on using PBMC-engrafted NSG™ mice as they relate to testing bispecific antibody efficacy and potentia
Watch Video
In September 2017, the Food and Drug Administration (FDA) approved the first CAR-T treatment for B-cell acute lymphoblastic leukemia, specifically for children and young adults who no longer...
Learn More
Hongyuan Yang, M.D., "Dose-Response and Time Course of TGN1412 Induced Human Cytokines in a Humanized PBMC Mouse Model for Cytokine Release Syndrome"
Watch Video
This webinar highlights recent advances and future directions using xenografted humanized NSG™ mice with functional human immune cells, to evaluate cancer immunotherapies.
Watch Video
The JAX Clinical Knowledgebase (CKB) is a valuable resource that can be utilized to interpret somatic variants and identify the most relevant therapy via efficacy evidence annotations. Here is a...
Learn More
Loading More...
